IRIS
PERA, MARIA CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.154
NA - Nord America 1.586
EU - Europa 1.002
SA - Sud America 741
AF - Africa 195
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.681
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.498
SG - Singapore 1.355
BR - Brasile 550
VN - Vietnam 484
CN - Cina 427
BD - Bangladesh 332
IT - Italia 321
HK - Hong Kong 274
NL - Olanda 218
FR - Francia 158
ZA - Sudafrica 133
AR - Argentina 74
RU - Federazione Russa 59
DE - Germania 52
IN - India 48
IQ - Iraq 41
AT - Austria 37
GB - Regno Unito 35
IE - Irlanda 35
CO - Colombia 33
MX - Messico 32
CA - Canada 25
EC - Ecuador 24
TR - Turchia 23
PK - Pakistan 22
MA - Marocco 20
JP - Giappone 16
VE - Venezuela 16
PH - Filippine 15
PY - Paraguay 15
SA - Arabia Saudita 14
ID - Indonesia 13
PL - Polonia 12
UA - Ucraina 11
UY - Uruguay 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
KR - Corea 10
TN - Tunisia 10
CL - Cile 9
ES - Italia 9
LT - Lituania 9
JM - Giamaica 8
SE - Svezia 8
DZ - Algeria 7
AZ - Azerbaigian 6
BG - Bulgaria 6
IL - Israele 6
PE - Perù 6
TH - Thailandia 6
DO - Repubblica Dominicana 5
EG - Egitto 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
HN - Honduras 4
KZ - Kazakistan 4
LB - Libano 4
CH - Svizzera 3
ET - Etiopia 3
GE - Georgia 3
GT - Guatemala 3
IR - Iran 3
MY - Malesia 3
PT - Portogallo 3
RO - Romania 3
TT - Trinidad e Tobago 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
EE - Estonia 2
FI - Finlandia 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CM - Camerun 1
HU - Ungheria 1
KW - Kuwait 1
LC - Santa Lucia 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 6.677
Salva come PNG Salva come JPEG
Città #
Singapore 603
San Jose 508
Hong Kong 258
Beijing 156
Ho Chi Minh City 151
Ashburn 145
Dallas 128
Hanoi 125
Santa Clara 124
Johannesburg 120
Groningen 103
Lauterbourg 96
Los Angeles 57
New York 47
Boardman 45
São Paulo 43
Buffalo 41
Moscow 36
Milan 35
Dublin 34
Rio de Janeiro 34
Nuremberg 25
Council Bluffs 22
Haiphong 21
Munich 17
Bologna 16
Parma 16
Rome 16
Shanghai 16
Brasília 14
Da Nang 14
Hefei 14
Naples 13
Tokyo 13
Vienna 13
Baghdad 12
Biên Hòa 11
Quito 11
Amman 10
Chicago 10
San Francisco 10
Ankara 9
Can Tho 9
Columbus 9
Nairobi 9
Ninh Bình 9
Tashkent 9
Toronto 9
Turin 9
Frankfurt am Main 8
Guangzhou 8
Hải Dương 8
Warsaw 8
Atlanta 7
Boston 7
Caracas 7
Curitiba 7
Dhaka 7
London 7
New Delhi 7
Tianjin 7
Baku 6
Belo Horizonte 6
Bogotá 6
Brooklyn 6
Catania 6
Houston 6
Montevideo 6
Phoenix 6
Thái Nguyên 6
Amsterdam 5
Aracaju 5
Asunción 5
Buenos Aires 5
Carpi 5
Casablanca 5
Denver 5
Erbil 5
Forlì 5
Guarulhos 5
Hyderabad 5
Istanbul 5
Jeddah 5
Karachi 5
Karbala 5
Kingston 5
Mexico City 5
Montreal 5
Recife 5
Rosario 5
Seattle 5
Stockholm 5
Brescia 4
Bắc Ninh 4
Campinas 4
Caxias do Sul 4
Charlotte 4
Conselheiro Lafaiete 4
Dammam 4
Formosa 4
Totale 3.539
Salva come PNG Salva come JPEG
Nome #
Airway Colonization in Children with Medical Complexity: Challenges and Management Strategies 155
Beyond Muscle Weakness: Unraveling Endocrine and Metabolic Dysfunctions in Duchenne Muscular Dystrophy, a Narrative Review 102
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence 99
An observational study of functional abilities in infants, children, and adults with type 1 SMA 91
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 90
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 89
Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review 89
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 84
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 83
Risdiplam in Type 1 Spinal Muscular Atrophy 82
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression 82
What did we learn from new treatments in SMA? A narrative review 81
Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 79
An observational study of functional abilities in infants, children, and adults with type 1 SMA 76
Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy 76
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 75
Early neurodevelopmental assessment in Duchenne muscular dystrophy 75
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 75
Spinal muscular atrophy — insights and challenges in the treatment era 74
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 74
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 73
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 72
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 71
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 70
Assessing floppy infants: a new module 69
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 69
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 68
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 68
Clinical Variability in Spinal Muscular Atrophy Type III 68
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 67
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 66
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 66
Developmental milestones in type I spinal muscular atrophy 65
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 65
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 63
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 63
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 63
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 63
Longitudinal natural history of type I spinal muscular atrophy: A critical review 63
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 62
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 62
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 62
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 61
Early treatment of type II SMA slows rate of progression of scoliosis 61
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 60
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 60
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 60
Developmental milestones in type I spinal muscular atrophy 60
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 59
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 59
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded 59
Design and Usability Testing of a Novel Internet-Delivered Cognitive Behavioral Therapy (iCBT) Software Platform for Children with Anxiety 59
Traumatic Childbirth Experiences and their Association with Postpartum Psychiatric Disorders: A Systematic Review 59
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 58
Sleep disorders in spinal muscular atrophy 58
Old measures and new scores in spinal muscular atrophy patients 58
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 58
Revised upper limb module for spinal muscular atrophy: Development of a new module 57
Italian validation of the SMA independence scale–upper limb module 57
Development of an academic disease registry for spinal muscular atrophy 56
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 56
Long term follow-up of scoliosis progression in type II SMA patients 56
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 56
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 55
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 55
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 55
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 55
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 54
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 54
How to Manage Electrical Status Epilepticus in Sleep 54
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 54
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 53
Revised upper limb module for spinal muscular atrophy: 12 month changes 53
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 53
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 53
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 52
Neonatal hypotonia and neuromuscular conditions 52
Predominant distal muscle involvement in spinal muscular atrophy 52
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 51
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 51
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 51
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 51
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 51
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 51
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 50
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 50
Gain and loss of abilities in type II SMA: A 12-month natural history study 49
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 49
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 49
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 49
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 47
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 47
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 47
Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy 47
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 47
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 47
Treatment of spinal muscular atrophy 47
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 46
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 45
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 45
Totale 6.287
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.631 0 0 318 55 85 97 50 55 234 215 111 411
2025/20265.172 325 491 635 479 585 202 552 120 564 451 470 298
Totale 6.803